Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer

  • STATUS
    Recruiting
  • participants needed
    60
  • sponsor
    Tokyo University
Updated on 19 October 2021
carcinoma
metastasis
cancer chemotherapy
adjuvant chemotherapy
lung carcinoma

Summary

In this clinical study, the investigators evaluate the efficacy and safety of S-588410 in patients who underwent an adjuvant chemotherapy after the complete resection of non-small-cell lung cancer.

Description

In this phase II trial, the investigators evaluate the efficacy and safety of S-588410 containing oncoantigens-derived HLA-A2402-restricted epitope peptides in patients with HLA-A2402 who underwent an adjuvant chemotherapy after the complete resection of non-small-cell lung cancer.

Details
Condition Non-Small Cell Lung Cancer, nsclc
Treatment Placebo, S-588410
Clinical Study IdentifierNCT02410369
SponsorTokyo University
Last Modified on19 October 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note